Raveesha Peeriga

Raveesha Peeriga

Auto-generated profile, based on publicly available information

Raveesha Peeriga

Department of Pharmacognosy, V. V. Institute of Pharmaceutical Sciences, Seshadri Rao Knowledge Village, Gudlavalleru, Andhra Pradesh, India

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2024 in Biomedical and Pharmacology Journal
Verified
Journal Article
Open access
RPRaveesha Peeriga
Raveesha Peeriga
SAS.A. Mohamed Shiek Arabath
S.A. Mohamed Shiek Arabath
Krishnaveni ManuboluKrishnaveni Manubolu
Krishnaveni Manubolu
BTBency Baby Thelappilly
Bency Baby Thelappilly
LYLakshmi Chakradhar Yarlagadda
Lakshmi Chakradhar Yarlagadda
Biomedical and Pharmacology Journal (BPJ) is an international, open access, peer reviewed, quarterly research journal.

30 June 2025 in Biomedical and Pharmacology Journal
Verified
Journal Article
Open access
RPRaveesha Peeriga
Raveesha Peeriga
Krishnaveni ManuboluKrishnaveni Manubolu
Krishnaveni Manubolu
VNVenkateshan Narayanan
Venkateshan Narayanan
PKPRASHANTH KUMAR KATTA
PRASHANTH KUMAR KATTA
NJNuraddeen Ibrahim Jaafar
Nuraddeen Ibrahim Jaafar
NSNagul Meeravali Shaik
Nagul Meeravali Shaik
The physiological and immunological profile of children makes pediatric viral infections particularly difficult. Although pediatric populations are a high risk for hospitalization, pediatric-specific antiviral therapy is largely unexplored, resulting in long delays between pediatric drug approvals and commercialization. This chapter discusses inadequacies in the antiviral drug development and administration for pediatric patients and highlights the importance of age specific approaches including regulatory hindrances to approving children's drugs, and the inhumane nature of performing trials in children. The role that Pediatric Research Equity Act (PREA) and the Best Pharmaceuticals for Children Act (BPCA) played in promoting pediatric focused drug research are highlighted. The chapter seeks to encourage cooperation between pediatricians, pharmaceutical developers, and regulatory bodies, in support of the notion that therapeutic antiviral should be truly pediatric centric. Optimizing treatment outcomes is essential to the global health of young patients and these efforts are required.

21 March 2025 in Current Indian Science
Verified
Journal Article
Open access
PDF file
Krishnaveni ManuboluKrishnaveni Manubolu
Krishnaveni Manubolu
RPRaveesha Peeriga
Raveesha Peeriga
Introduction: Vildagliptin is a dipeptidyl peptidase 4-related inhibitor that is often utilised in the treatment of type-2 diabetes. It is possible that sustained therapeutic levels of vildagliptin for a prolonged length of time might be achieved by controlled release of the drug in the gastrointestinal system, which would result in an improvement in the efficacy of treatment. Due to their high biocompatibility and biodegradability, biopolymers, such as alginate (sodium), pectin, and xanthan gum, are frequently utilized in drug delivery systems. This is because these biopolymers are good alternatives for the development of controlled-release formulations. Aim: This study aimed to formulate and in vitro evaluate the vildagliptin microsphere using pectin and xanthan gum. Materials and Methods: The delivery of vildagliptin was accomplished by the development of beads that were constituted of sodium alginate-pectin and sodium alginatexanthan gum. Adjusting the proportions of sodium alginate, pectin, and xanthan gum resulted in the production of pH-sensitive beads throughout the synthesis. This was accomplished through the use of a calcium chloride (CaCl2)-induced ionic gelation approach. Results: The FTIR revealed the compatibility of medicines and polymers. The synthesized beads were tested for scanning electron microscopy, differential scanning calorimetry, drug content, swelling ratio, and in vitro dissolution analysis. The microscopic pictures showed beads of spherical shape and mostly semi-spherical with a broken and rough surface. Swelling was found to be pH-dependent, indicating that water absorption might be minimal in an acid medium and high in an alkaline pH condition. The in-vitro dissolving study depicted controlled drug release. Conclusion: This study recorded the successful formulation of vildagliptin microspheres using sodium alginate, pectin, and xanthan beads for the controlled release of vildagliptin.